Mediwound Ltd

NASDAQ MDWD

Data sourced from

and

Daily

Download Data

Mediwound Ltd Price to Book Ratio (P/B) on June 03, 2024: 6.75

Mediwound Ltd Price to Book Ratio (P/B) is 6.75 on June 03, 2024, a 189.74% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Mediwound Ltd 52-week high Price to Book Ratio (P/B) is 7.28 on May 28, 2024, which is 7.82% above the current Price to Book Ratio (P/B).
Mediwound Ltd 52-week low Price to Book Ratio (P/B) is 1.89 on September 08, 2023, which is -71.96% below the current Price to Book Ratio (P/B).
Mediwound Ltd average Price to Book Ratio (P/B) for the last 52 weeks is 3.28.

NASDAQ: MDWD

Mediwound Ltd

CEO	Prof. Lior Rosenberg M.D.
IPO Date	March 20, 2014
Location	Israel
Headquarters	42 Hayarkon Street, Yavne, Israel, 8122745
Employees	100
Sector	Healthcare
Industry	Biotechnology

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Key trends